Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.92 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.53 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878913 | 1.00 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL12971085 | 1.00 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL18251819 | 1.00 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL5878943 | 1.00 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL6294130 | 1.00 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL5879079 | 1.00 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL5878803 | 1.00 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL5879028 | 1.00 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL5879047 | 1.00 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL5879069 | 1.00 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023610-B2 | Ligands for prevention of neurotoxicity of the alzheimer's disease related amyloid-beta peptide | ALPHABETA AB (SE) | 2018-07-17 | — | — | US | disclosed |
| US-20160340387-A1 | NOVEL LIGANDS FOR PREVENTION OF NEUROTOXICITY OF THE ALZHEIMER'S DISEASE RELATED AMYLOID-BETA PEPTIDE | ALPHABETA AB (SE) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023610-B2 | Ligands for prevention of neurotoxicity of the alzheimer's disease related amyloid-beta peptide | APP, BACE1, PSEN1 | ACE2 895/4885BLM 3687/4885GPR84 807/4885 |
| US-20160340387-A1 | NOVEL LIGANDS FOR PREVENTION OF NEUROTOXICITY OF THE ALZHEIMER'S DISEASE RELATED AMYLOID-BETA PEPTIDE | APP, BACE1, PSEN1 | ACE2 932/4885BLM 4087/4885GPR84 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.